go back

Brexucabtagene Autoleucel (Tecartus)

Rhode Island rates for HCPCS C9073

Brexucabtagene autoleucel, up to 200 million autologous anti-CD19 CAR positive viable T cells, including leukapheresis and dose preparation procedures, per therapeutic dose

Rates data updated October 2026.

How much rates vary

Facilitymedian $398,107 · 10th to 90th $380,189 to $416,869Professionalmedian $407,380 · 10th to 90th $407,380 to $407,380
facility $398,107professional $407,380

Distribution of negotiated rates across all payers (price axis is log-scale). Small sample; interpret with caution. Need provider-level prices or 24+ months of history? Contact us.

Rates by insurance carrier

Insurance Carrier
BCBS Rhode Island
Setting
Facility
Modifier
None
Typical Low
$380,189.40
Median
$398,107.17
Typical High
$416,869.38
BCBS Rhode Island
Setting
Professional
Modifier
None
Typical Low
$407,380.28
Median
$407,380.28
Typical High
$407,380.28